Introduction
============

Corticosteroids seem to be among the hormones with the most important effects on the brain function. Indeed, corticosteroids have been associated with effects on mood, stress, anxiety, sleep, appetite, as well as cognition ([@B66]; [@B118]; [@B18]).

Once released from the adrenal cortex, cortisol, the main glucocorticoid in humans, easily crosses the blood--brain barrier, owing to its lipophilic character ([@B118]). Cortisol binds to specific intracellular receptors in the brain, in particular in regions implicated in cognitive functions ([@B73]; [@B21]; [@B114]). Once activated, these receptors bind to " hormone response elements" in the DNA and regulate the transcription of target genes ([@B49]).

The resulting effects on cognition seem to be complex and involve several cognitive domains ([@B66]; [@B62]; [@B106]; [@B37]; [@B114]). Different levels of cortisol likely produce different and even sometimes opposite effects ([@B23]; [@B49]). While some of these effects are acute ([@B67]; [@B70]; [@B76]), some appear to be long-lasting and may even involve long-term changes in the brain structure ([@B37]).

Altered Hypothalamic-Pituitary-Adrenal (HPA) axis functioning, and in particular high cortisol levels in the elderly have been associated with an increased risk for dementia and Alzheimer's disease (AD) ([@B69]; [@B94]; [@B30]; [@B81]).

A better understanding of these interrelationships between cortisol, cognition and dementia may open the door to new prevention and therapeutic options involving the HPA axis. The effects of cortisol on emotional memory had already led to therapeutic trials of corticosteroids and corticosteroid receptor antagonists/modulators in AD ([@B87]), as well as in treating or preventing post-traumatic stress disorder (PTSD) ([@B21]), as well as in treating depression ([@B119]; [@B56]).

Glucocorticoid Receptors and Cortisol Effects on Cognition
==========================================================

Cortisol exerts its effects on cognition through two types of receptors: type I (Mineralocorticoid Receptors, MRs) and type II (Glucocorticoid Receptors, GRs) ([@B49]; [@B21]). Surprisingly, the MRs display 6 to 10 times higher affinity for glucocorticoids, mainly cortisol, than GRs ([@B23]; [@B49]).

These receptors are expressed differently throughout the brain. Indeed, the hippocampus, mainly implicated in episodic memory, expresses both MRs and GRs, whilst the prefrontal cortex, primarily responsible for executive functions, only expresses GRs ([@B66]; [@B73]). While MRs have been associated with positive/enhancing effects on the cognitive performance, GRs have, on the contrary, been linked to negative inhibitory effects. In this regard, it has been found that infusion of a GR antagonist, but not of MR antagonist, in the medial prefrontal cortex of a mouse blocked the deleterious effects of glucocorticoids on working memory ([@B8]).

Cortisol effects on the hippocampus-related cognitive performance have often been described by the means of an inverted-U shape plot ([Figure 1](#F1){ref-type="fig"}). Indeed, in the hippocampus, where both GRs and MRs are expressed, moderate levels of cortisol only activate the receptors with the higher affinity, i.e., MRs, leading to memory enhancement effects. As cortisol levels increase, this positive effect increases till MRs are saturated. Starting from this point, as cortisol levels rise, GRs are increasingly activated thus leading to increasingly detrimental effects on the memory. Distinctly, the effects of cortisol on executive functions are likely more linear. Since the prefrontal cortex region, mostly responsible for executive functions, only expresses GRs, higher levels of cortisol may lead to worsened executive functioning ([Figure 2](#F2){ref-type="fig"}; [@B66]; [@B73]). The fact that both adrenal insufficiency and Cushing's disease have been associated with impaired declarative memory ([@B33]; [@B110]) bolsters this biphasic effect hypothesis. Another argument is that the administration of the MR agonist fludrocortisone has been found to improve verbal and visuospatial memory performance in young as well as elderly healthy subjects ([@B47]); whereas the administration of hydrocortisone (mimicking the endogenous cortisol effects on both GRs and MRs) has been shown to enhance at lower doses yet impair at higher doses verbal memory retrieval in healthy subjects ([@B26]).

![Dose--response relationship between the memory performance and the cortisol levels. The first part of the plot shows that memory performance increases as cortisol levels increase (due to the activation of mineralocorticoid receptors or MRs). As soon as the MRs are saturated, further increase in cortisol levels activates the glucocorticoids receptors or GRs and memory performance decreases. Adapted with permission from [@B66].](fnagi-11-00043-g001){#F1}

![Hypothetical dose--response relationship between the executive functions performance and the cortisol levels. As the prefrontal cortex only expresses GRs, the higher the cortisol levels, the poorer the executive functions performance.](fnagi-11-00043-g002){#F2}

These effects that cortisol exerts on the brain structures involved in cognition are possibly mediated by modifications in responses to serotonin, in β-adrenergic receptor activation, in calcium influx, as well as in long-term potentiation (LTP), a process referring to a long-term strengthening of synaptic connections contributing to memory formation and consolidation ([@B49]; [@B66]). Indeed, GR activation facilitates β-adrenergic signaling thus leading to the formation of adenosine 3′,5′-cyclic monophosphate (cAMP) and cAMP-dependent protein kinase (PKA). This pathway, once activated, is thought to inhibit the medial prefrontal cortex thus leading to an impairment in frontal functions, in particular working memory ([@B74]; [@B8]). Glucocorticoids have also been found to display certain effects on the hippocampus via actions on the serotoninergic system following the same biphasic pattern as described in [Figure 1](#F1){ref-type="fig"}. Indeed, glucocorticoids can promote via MRs and, at the same time, inhibit via GRs the 5HT1A activation in hippocampal CA1 pyramidal cells ([@B22]).

Moreover, glucocorticoids have been reported to alter LTP in opposite directions depending on the MR/GR activation ratio: when the MR/GR activation ratio is high (central part of the inverted U-shaped plot, [Figure 1](#F1){ref-type="fig"}), LTP is enhanced thus improving long-term memory consolidation. On the contrary, when the MR/GR ratio is low (extremes of the inverted U-shaped plot, [Figure 1](#F1){ref-type="fig"}), LTP is suppressed thus worsening long-term memory consolidation ([@B23]; [@B66]).

In clinical studies, most studies examining the link between cortisol levels and global cognitive performance among non-demented older adults found that higher cortisol levels have been associated with poorer overall cognitive performance ([@B66]; [@B61]; [@B83]; [@B97]). Likewise, most ([@B9]; [@B37]; [@B100]; [@B83],[@B84]; [@B28]), even though not all ([@B61]) studies exploring the relationship between episodic memory and cortisol levels have found an association between elevated cortisol and poorer episodic memory among older adults without dementia. These findings suggest that, even at levels that are within the normal range, cortisol can still activate GRs, and not just MRs. This also suggests that relatively small differences in cortisol levels can exhibit significant effects on memory performance. Studies exploring the relationship between cortisol levels and prefrontal cortex-mediated cognitive functions, mainly executive functions, processing speed and working memory, have found more discrepant results: while the expected negative association was reported in certain studies ([@B61]; [@B9]; [@B37]), other studies failed to find such an association ([@B83],[@B84]; [@B28]).

The differences in populations, assessment tools, as well as the likely effects of possible confounding factors including age, gender, educational level, as well as other neuroendocrine and psychological factors might explain these discrepancies.

Cortisol and Cerebral Structural Changes
========================================

High cortisol has also been linked to decreased volume of several brain regions involved in cognitive functions. In fact, in a study by [@B37] involving 4244 non-demented subjects, elevated evening cortisol was found to be associated with decreased volumes in all brain regions, in particular the gray matter ([@B37]). Similar findings have been reported in the dementia-free Framingham Heart Study participants: elevated cortisol was associated with decreased total brain volume, in particular decreased occipital and frontal gray matter volumes. In the same study, increased cortisol levels were associated with some microstructural changes, specifically in the corpus callosum and the posterior corona radiate ([@B28]).

In addition, high levels of cortisol have been linked to hippocampal atrophy ([@B106]). This atrophy can be the consequence of the exposure to increased cortisol levels. Indeed, in Cushing's disease, the observed hippocampal atrophy is reversed following treatment and normalization of the cortisol levels ([@B101]). Yet, this atrophy can also be a cause of the elevated cortisol levels. Indeed, the hippocampus exerts an inhibitory effect on the HPA axis activity, and hence hippocampal atrophy might disinhibit the HPA axis leading to increased cortisol ([@B37]; [Figure 3](#F3){ref-type="fig"}).

![**(A)** In normal circumstances, the CRF released by the hypothalamus activates ACTH release by the pituitary gland, which stimulates the adrenal glands to secrete cortisol. Cortisol inhibits its own secretion via a negative feedback loop. The hippocampus inhibits the hypothalamo-pituitary-adrenal axis. **(B)** When cortisol is elevated, it can induce hippocampal atrophy, which "lifts the brake" on the hypothalamo-pituitary-adrenal axis. The resulting cortisol increase induces further hippocampal atrophy, resulting in a vicious circle. CRF, corticotropin-releasing factor; ACTH, Adrenocorticotropic hormone.](fnagi-11-00043-g003){#F3}

These effects on the hippocampal volume may be partly due to changes in brain-derived neurotrophic factor (BDNF) expression in the hippocampus ([@B105]). Similarly to their effects on cognitive performance, MR activation seems to increase whereas GR activation seems to decrease BDNF expression in the hippocampus ([@B54]; [@B105]).

In a study by [@B19] elevated salivary cortisol levels at the start and at the end of a cognitive task appointment have been associated with a poorer white matter structure, i.e., greater white matter hyperintensity volume and/or elevated general factor of tract mean diffusivity. These findings suggest that aside from the "acute effects" of cortisol on cognition, chronically elevated cortisol levels likely bring about brain structural changes that may reflect long-term cognitive deficits.

HPA-Axis Dysregulation, Cortisol and Alzheimer's Disease Pathology, Disease Risk and Clinical Course
====================================================================================================

Glucocorticoids have been reported to promote oxidative stress and to increase amyloid β (Aβ) peptide toxicity in cultured hippocampal neurons ([@B40]). Besides, in a mouse model of AD, elevated cortisol has been linked to exacerbated Aβ peptide and tau pathology in the brain ([@B41]).

In primates, year-long high-dose exposure to glucocorticoids was associated with decreased insulin-degrading enzyme levels, a candidate protease for the clearance of Aβ in the brain. At the same time, the Aβ1-42/Aβ1-40 ratio was increased indicating a relative shift toward increased production of the more brain toxic Aβ1-42 ([@B57]).

In a cross-sectional study examining the links between cardiovascular risk factors and Aβ brain burden as determined by Pittsburgh Compound B-positron emission tomography (PiB-PET), an association has been found between plasma cortisol and Aβ brain burden ([@B111]).

Together, these findings suggest that increased cortisol may induce and/or exacerbate cerebral AD pathology by increasing Aβ brain burden, tau pathology as well as oxidative stress, which can all contribute to neurodegeneration. Effects on Aβ likely entail decreasing Aβ clearance as well as promoting the cleavage of Aβ into the most toxic compound (Aβ1-42) ([@B57]).

The aforementioned cerebral changes associated with elevated cortisol likely translate into findings of associations between increased cortisol levels and clinical features of AD, as shown in several clinical studies that reported increased cortisol levels in patients with clinical AD dementia ([@B27]; [@B90]; [@B30]), and cortisol levels have even been found to correlate with the severity of the cognitive impairment ([@B85]; [@B124]).

A prospective study by [@B30] S found that elevated cortisol (as measured by the urinary free cortisol/creatinine ratio) and elevated intra-subject cortisol variability (as measured by the within-person urinary free cortisol/creatinine ratio variability) were associated with a 1.31- and 1.38-times increase in AD risk. Furthermore, in cognitively healthy older adults with Aβ positive PET imaging, high cortisol levels have been found to be associated with a faster decline in global cognition, in episodic memory, as well as in executive functioning, independently of age, sex, APOE genotype, or anxiety symptoms ([@B86]). In a population based cohort study in 537 non-demented older adults (65 years or more at baseline), we found salivary cortisol day profiles to be not associated with faster cognitive decline over an average 5.3 years. However, preliminary analysis suggests that higher morning salivary cortisol measures may be associated with slight decline in global cognition ([@B2]).

Higher plasma cortisol levels in patients with AD dementia have been associated with a more rapid cognitive decline in some studies ([@B85]; [@B48]). Similarly, [@B20] found that high plasma cortisol levels were associated with faster cognitive decline in individuals with very mild or mild AD dementia.

In a cohort study from the Alzheimer Disease Neuroimaging Initiative (ADNI) investigating biomarkers able to predict progression from mild cognitive impairment (MCI) to AD within 1--6 years, plasma cortisol was one of the six biomarkers found to provide an accurate prediction ([@B63]).

Moreover, cortisol concentrations in the cerebrospinal fluid (CSF) have been found to be higher in subjects with dementia and MCI due to AD compared to control subjects ([@B90], [@B91]). In MCI due to AD, high CSF cortisol was also predictive of a more rapid cognitive decline ([@B91]). Hence, elevated cortisol appears to contribute to exacerbate AD brain pathology, thereby contributing to the disease progression both pathologically and clinically. Cortisol levels appear to be increased at early stages of AD, and fasting plasma and CSF cortisol levels may even be pre-clinical markers ([@B81]).

These findings may be explained by increased Aβ neurotoxicity related to higher cortisol levels as well as neurodegeneration and functional impairment of the hippocampus occurring early in the course of the disease as both a consequence of exposure to high cortisol levels and a cause of HPA axis disinhibition, hence a vicious circle ([@B37]).

Cortisol, Cognition and Mediating Factors
=========================================

Certain factors may further explain the links between cortisol, cognitive impairment and dementia. Indeed, some of these factors may bring about HPA axis alterations that could affect cognition and the risk for dementia, in particular AD. These factors may include life events ([@B83]), personality ([@B84]; [@B107]; [@B108]), sleep disorders ([@B42]), depression ([@B96]).

At the same time, some other factors such as metabolic syndrome, insulin resistance and effects on inflammation may mediate the effects of cortisol on cognition and brain structural changes ([@B53]; [@B72]).

Cortisol, Cognition, Trauma and Life Events
-------------------------------------------

Early trauma (of physical, sexual or emotional nature) has been linked to long-term cognitive deficits in adulthood (consisting in impaired spatial working memory and pattern recognition memory) in a study by [@B71]; however, this finding was not replicated in other studies ([@B95]). Early stress has also been shown to be associated with structural and functional changes in brain regions involved in cognitive functions, including the frontal cortex as well as the hippocampus ([@B68]).

Early trauma is also one of the most important established risk factors for PTSD. PTSD has been shown to be associated with an increased risk of dementia in both genders over an average of 8 years of follow-up (hazard ratio: 1.73\[1.47, 2.02\]) ([@B32]). Nevertheless, [@B14] found that the long-term cognitive deficits associated with PTSD were likely independent of earlier childhood adversity.

Aside from early trauma and PTSD, stressful life events have often been associated with HPA activation. Yet, some studies, conversely, showed decreased cortisol following stressful life events ([@B77]; [@B21]). Results of the studies exploring the relationship between life events and cognition have been discrepant. On the one hand, several studies highlighted associations between stressful events and poorer subsequent cognitive performance, in particular in memory and executive functions ([@B121]; [@B115]; [@B113]; [@B66]) above and beyond the impact of depression ([@B17]). Importantly, stressful events have been also associated with an elevated risk of late-life dementia ([@B50]) and late-life cerebral atrophy, and white matter lesions ([@B51]). On the other hand, other studies failed to find any association between stressful life events and cognitive performance in the elderly ([@B116]; [@B34]; [@B104]) and some even showed a possible improvement in cognition following certain stressful events ([@B24]).

In a study exploring the mediation hypothesis between cortisol, life events and cognition in 796 non-demented subjects aged at least 65 we found elevated salivary cortisol levels to be linked to poorer cognitive performance, but this association was not related to life events ([@B83]).

These discrepancies regarding the relationships between life events and cortisol on the one hand, and life events and cognition on the other hand, may be explained by different life events displaying different effects on cortisol and thus on cognition ([@B83]).

Cortisol, Cognition and Personality
-----------------------------------

High neuroticism is the personality trait most consistently often associated with high cortisol ([@B12]; [@B112]; [@B78], [@B79]; [@B92]; [@B122]; [@B39]; [@B80]; [@B36]). However, other studies found no association ([@B1]; [@B99]; [@B31]), or even an opposite link ([@B7]; [@B60]).

Higher neuroticism has also been reported to be cross-sectionally linked to lower cognitive performance above and beyond the effects of depression ([@B52]; [@B11]), especially to poorer episodic memory ([@B52]; [@B75]; [@B55]). In addition, high neuroticism scores have been found in association with elevated risk of AD ([@B109]).

A few studies examined the relationship between the other personality traits and cognitive performance and risk of dementia. Lower pre-morbid conscientiousness, agreeableness, openness and extraversion have been associated, although not consistently, with lower cognitive performance and higher risk for AD ([@B109], [@B108]; [@B107]). In a cohort of memory clinic patients and cognitively healthy elderly volunteers we found lower extraversion and openness to correlate with CSF markers of AD pathology: tau, ptau-181, tau/Aβ1--42, and ptau-181/Aβ1--42 ratios, but not with the Aβ1--42 level ([@B107]).

In a population-based cohort study examining the interrelationships between cortisol, cognition and personality traits, salivary cortisol did not seem to mediate the link between personality traits and cognitive deficits ([@B84]).

Besides methodological differences, these observed discrepancies may be due to the impact of depression and/or anxiety which has been controlled for in a few studies but not in others, but also to the difficulties (in cross-sectional studies, mainly) to disentangle pre-morbid personality traits from the personality modifications accompanying the cognitive decline.

Cortisol, Cognition and Sleep Disorders
---------------------------------------

Cognitive impairment has been associated with more time spent in stage N1 (first step of non-rapid eye movement sleep) and less in stage N3 (third step of non-rapid eye movement sleep) and in REM sleep, lower sleep efficiency, and more wake after sleep onset, as well as more severe sleep disordered breathing (as evidenced by higher apnea/hypopnea index or AHI, and higher oxygen desaturation index or ODI) ([@B42]).

In a study of the same research group, involving 456 elderly non-demented subjects, obstructive sleep apnea (OSA) has been found to be linked to cognitive impairment, but the relationship did not appear to be mediated by diurnal cortisol levels ([@B43]).

In other studies, OSA has been associated with increased nocturnal plasma cortisol levels ([@B16]). [@B29] found that higher night-time cortisol was associated with worse cognitive performance, mainly affecting memory, above and beyond the apnea severity in a sample of patients with OSA.

Taken together, the results of these studies highlight links between cognitive performance and sleep disorders on the one hand, and between cortisol levels and cognitive functioning on the other hand, but do not provide evidence to support that cortisol may actually mediate the relationship between sleep disorders and cognitive impairment.

Cortisol, Cognition and Depression
----------------------------------

Depression has been associated, on the one hand with HPA axis hyperactivity and impaired negative feedback ([@B3]), and on the other hand with cognitive deficits involving attention, episodic memory and executive functions ([@B96]). Depression has also been tied to late-life dementia, in particular with vascular and AD dementia ([@B13]). This association is not just a mere comorbidity, as late-life depression may also be a risk factor for both AD and vascular dementia ([@B25]; [@B45]). In the AGES-Reykjavik population-based study ([@B38]), both current major depressive disorder and high evening cortisol levels were associated with an higher risk of incident AD and non-AD dementia, but cortisol did not seem to be a major factor explaining the relation between depression and risk of dementia.

Some of the observed cognitive deficits in verbal and visual memory and executive functions may remain present even after the depressive symptoms fully remitted ([@B46]; [@B93]; [@B96]). Likewise, the HPA axis abnormalities associated with depression may persist even after remission ([@B65]; [@B96]), possibly constituting trait rather than state markers for depression, even though this remains a matter of debate ([@B124]; [@B96]).

Remission status in depression did not moderate the association between cognitive performance and the Dexamethasone suppression test ratio or the cortisol awakening response (CAR), defined by the increase in cortisol secretion after awakening ([@B35]). However, remission appeared to moderate the association between cortisol slope defined by the difference between maximal and minimal cortisol levels during the nyctemera, and certain cognitive tasks assessing processing speed and executive function ([@B96]). HPA axis alteration in depression may inhibit neurogenesis, partly through reducing BDNF which is involved in hippocampal neurogenesis, thus possibly explaining one of the mechanisms by which depression may be a risk factor for AD ([@B45]).

Delirium is common in AD, and it is associated with more rapid clinical disease progression ([@B89]). Depression symptoms and cognitive impairment have been independently associated with higher risk of developing delirium. In a yet-to be-published study by the same team, increased cortisol levels have been observed in patients with delirium suggesting HPA axis dysregulation to be involved in the pathophysiology of delirium. In a cohort of elderly patients undergoing elective cardiac surgery, pre-operative geriatric depression scale scores were found to predict post-operative delirium. However, pre-operative morning plasma cortisol levels were not associated with post-operative delirium in this study.

Whether and how HPA axis dysregulation and increased cortisol levels may contribute to the magnitude of cognitive and non-cognitive symptoms in AD, needs further investigation. In a study in patients with AD dementia, plasma cortisol levels have been shown to reflect the degree of cognitive deficits in AD dementia rather than the severity of the comorbid depression ([@B124]).

Altogether, these data suggest that, mostly, cognitive deficits linked to increased cortisol and HPA axis dysregulation cannot be entirely explained by a co-occurring depressive disorder. AD pathology may exacerbate HPA axis dysregulation which may contribute to the manifestation of depressive symptoms and to the severity of cognitive impairment and increase the risk of other non-cognitive syndromes, including delirium. Even though depression-associated HPA axis dysregulation may predispose to and/or exacerbate the course of AD ([@B45]), studies suggest a link between HPA axis dysregulation and AD itself above and beyond depression.

Cortisol, Cognition and the Metabolic Syndrome
----------------------------------------------

Elevated cortisol levels have been tied to insulin resistance and metabolic syndrome, which in turn, have been associated with both AD and vascular dementia. ([@B53]; [@B72]). Hence, elevated cortisol may lead, through its metabolic syndrome-associated effects on glucose, blood pressure and lipids, to an increased cardiovascular risk ([@B59]). Indeed, higher cortisol has been associated with a higher number of carotid plaques ([@B44]). The resulting vascular lesions in the brain may directly induce cognitive disturbances, but can also contribute to the neurodegeneration observed in AD ([@B4]). Moreover, insulin resistance itself may negatively influence the amyloid cascade ([@B102]).

At the same time, AD-associated hypercortisolemia, present at very early stages, may also induce pre-diabetes. The resulting increased insulin secretion can further exacerbate the hypercortisolemia, thus possibly negatively affecting the course of AD ([@B81]).

Cortisol, Cognition and Inflammation
------------------------------------

While cortisol is generally known to exert broad anti-inflammatory effects, high cortisol levels may activate NACHT, LRR and PYD domains-containing protein 1 (NLRP-1) inflammasome in hippocampal neurons, thus promoting neuroinflammation and thereby neuronal injury ([@B123]).

Moreover, certain cytokines, in particular IL-1-Beta and IL-6, which are also known to be involved in the pathophysiology of AD, can activate the HPA axis ([@B10]). The resulting increased cortisol can reinforce the toxic effects on the hippocampus exerted by the pro-inflammatory cytokines ([@B103]), thus contributing to the pathophysiology of AD.

Cortisol and Potential Preventive and Therapeutic Interventions for Alzheimer's Disease:
========================================================================================

Since increased cortisol has been associated with both AD pathology and more rapid clinical disease progression, and since most detrimental effects of cortisol are likely exerted via GRs, therapeutic interventions targeting the GRs have been investigated. Indeed, the GR antagonist mifepristone has been shown to decrease both Aβ and tau load in the brain as well as to improve the pathologically induced cognitive impairments in a triple-transgenic (3xTg AD) mouse model of AD ([@B5]). In a similar way, mifepristone has been shown to reduce the hippocampal Aβ levels and rescue the cognitive deficits induced by early life stress in APP/PS1 transgenic mice ([@B64]). As these pathological processes start years or even decades before the onset of the first symptoms, cortisol lowering or cortisol effects modulating interventions in midlife may slow down the development of amyloid pathology and neurodegeneration, and prevent cognitive decline in later life ([@B58]; [@B64]). Such interventions could prove useful, in particular in subjects at risk for developing clinical AD ([@B86]) and prone to stress, and HPA-axis dysregulation. Prevention trials with focus on cortisol or HPA-axis in human subjects with normal cognition have not been reported so far, however.

One randomized controlled trial in a small sample of patients with mild to moderate AD dementia showed improvement of cognitive performance in memory tasks, but the premature termination did not allow any firm conclusions regarding efficacy ([@B88]). Other trials using mifepristone that were initiated were terminated without being published, indicating that these trials were not completed, or yielded negative results ([@B82]).

Also, several non-pharmacological intervention in subjects with MCI ([@B6]) or dementia ([@B120]; [@B98]) have shown cortisol lowering effects.

However, there has been some loss of interest in GR antagonists because of their side effects due to GRs being ubiquitous, especially as more selective molecules, namely GR modulators have been developed ([@B15]).

Glucocorticoid Receptor modulators have been shown to normalize basal glucocorticoid plasma levels, decrease hippocampal Aβ peptide deposition, inhibit neuroinflammation, and apoptotic processes, and improve cognitive performance in a mouse model of AD ([@B87]).

Another potential mechanism by which cortisol effects can be reduced pharmacologically is the inhibition of cortisol synthesis, one of the key enzymes being the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Currently, a phase II trial of an 11β-HSD1 inhibitor (UE2343) as a potential treatment for AD is being conducted ([@B117]).

Strengths and Limitations
=========================

This narrative review provides a concise overview of the different molecular, cellular, and clinical (including diagnostic, prognostic, and therapeutic) aspects of the interrelationships between cortisol, cognition, dementia, and AD. However, it does not cover all possible facets of these complex relationships. We focused on the most important and the most clinically relevant aspects of the topic, rather going in depth into one particular aspect of the topic.

Conclusion
==========

There is a growing body of evidence that increased cortisol may be deleterious for the late-life cognitive performance, and may be associated with an increased risk for cognitive decline and dementia, in particular dementia due to AD. In patients with AD, the increased cortisol at preclinical and early clinical stages is associated with a poorer prognosis and a more rapid cognitive decline. Increased cortisol may represent a pathophysiological mediator between stressful life events, personality, mood, and sleep, and may increase both the risk of AD and the extent of symptoms at clinical stages of the disease. Yet, the exact underlying mediating factors are not fully understood. Direct deleterious cortisol effects on the hippocampus and on the prefrontal cortex are likely, but also cortisol links with metabolic syndrome and neuroinflammation; and HPA axis disinhibition due to neurodegeneration are other possible mechanisms that may explain the association of cortisol with late-life cognitive impairment and AD.

Further studies are needed to confirm the value of cortisol levels as a possible preclinical marker associated with higher risk, and/or as a prognostic parameter in subjects with clinical AD. Future research may also bring in new HPA-based interventions for the prevention and/or management of symptoms, and of the clinical progression of AD.
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